

Istituto Oncologico della Svizzera Italiana

## Conferenze formative IOSI 2021

Mercoledì dalle 12h00 alle 13h00 - Gli eventi si terranno ONLINE fino a nuove disposizioni

- 20 gennaio**      [The importance of clinical trials in oncology and barriers to clinical trial participation](#)  
**Prof. Roger Von Moos**, Head of Medical Oncology and Hematology, Kantonsspital Graubünden, Chur (CH).  
President of the Swiss Group for Clinical Cancer Research (SAKK)
- 24 febbraio**      [Clinical research in rare entities: practice changing achievements of the IELSG](#)  
**Prof. Emanuele Zucca**, Vice Head medical oncology in the Oncology Institute of Southern Switzerland (IOSI), clinical director of International Extranodal Lymphoma Study Group (IELSG), Bellinzona (CH)
- 17 marzo**        [The surprising role of the gut microbiota in prostate cancer progression and therapy](#)  
**Prof. Andrea Alimonti**, Head Molecular Oncology of Institute of Oncology Research (IOR), Bellinzona (CH)
- 21 aprile**        [Updates on the treatment of NSCLC](#)  
**Prof. Miklos Pless**, Head of Oncology, Dep of Medical Oncology, Kantonsspital Winterthur (CH)
- 19 maggio**        [Bone health and cancer therapy](#)  
**Prof. Robert Coleman**, Emeritus Professor of Medical Oncology, University of Sheffield (UK)
- 16 giugno**        [Molecular screening of cancer patients: moving from precision to high-definition oncology](#)  
**Dr. Miguel Quintela-Fandino**, Head of the Breast Cancer Clinical Research Group, Director of the Clinical Research Program – CNIO, Head of Developmental Therapeutics - University Hospital Quiron Pozuelo (E)
- 15 settembre**    [DNA repair defects and their targeting in cancer](#)  
**Prof. Ruth Plummer**, Professor at Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University (UK)
- 13 ottobre**       [Update on CAR-T cells and future directions](#)  
**PD Dr. Urban Novak**, Department Medical Oncology, Inselspital / Bern University Hospital (CH)
- 17 novembre**    [New immunotherapy combinations. How to balance toxicity and increased efficacy?](#)  
**Prof. John Haanen**, Leader Research Theme Immunotherapy, Division of Molecular Oncology & Immunology, Netherlands Cancer Institute (NKI), Amsterdam (NL)

Sponsor principale



Sponsor

